CV disorder risks extend beyond COX-2-selectivity of NSAIDs

Gespeichert in:

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2007

Schlagwörter:	Celecoxib Naproxen Rofecoxib Ketorolac Meloxicam

Anmerkung:	© Adis International Ltd 2007

Übergeordnetes Werk:	Enthalten in: Inpharma weekly - Auckland : ADIS internat., 1975, 1606(2007), 1 vom: Sept., Seite 17-17
Übergeordnetes Werk:	volume:1606 ; year:2007 ; number:1 ; month:09 ; pages:17-17

Links:	Volltext

DOI / URN:	10.2165/00128413-200716060-00061

Katalog-ID:	SPR035299207

Internformat


LEADER	01000caa a22002652 4500
001	SPR035299207
003	DE-627
005	20230519112536.0
007	cr uuu---uuuuu
008	201007s2007 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00128413-200716060-00061 \|2 doi
035			\|a (DE-627)SPR035299207
035			\|a (SPR)00128413-200716060-00061-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a CV disorder risks extend beyond COX-2-selectivity of NSAIDs
264		1	\|c 2007
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Adis International Ltd 2007
650		4	\|a Celecoxib \|7 (dpeaa)DE-He213
650		4	\|a Naproxen \|7 (dpeaa)DE-He213
650		4	\|a Rofecoxib \|7 (dpeaa)DE-He213
650		4	\|a Ketorolac \|7 (dpeaa)DE-He213
650		4	\|a Meloxicam \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t Inpharma weekly \|d Auckland : ADIS internat., 1975 \|g 1606(2007), 1 vom: Sept., Seite 17-17 \|w (DE-627)373977859 \|w (DE-600)2127607-9 \|x 2230-6056 \|7 nnns
773	1	8	\|g volume:1606 \|g year:2007 \|g number:1 \|g month:09 \|g pages:17-17
856	4	0	\|u https://dx.doi.org/10.2165/00128413-200716060-00061 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_206
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4305
951			\|a AR
952			\|d 1606 \|j 2007 \|e 1 \|c 09 \|h 17-17

Indexfelder

matchkey_str	article:22306056:2007----::viodriketnbyncxslc
hierarchy_sort_str	2007
publishDate	2007
allfields	10.2165/00128413-200716060-00061 doi (DE-627)SPR035299207 (SPR)00128413-200716060-00061-e DE-627 ger DE-627 rakwb eng CV disorder risks extend beyond COX-2-selectivity of NSAIDs 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2007 Celecoxib (dpeaa)DE-He213 Naproxen (dpeaa)DE-He213 Rofecoxib (dpeaa)DE-He213 Ketorolac (dpeaa)DE-He213 Meloxicam (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1606(2007), 1 vom: Sept., Seite 17-17 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1606 year:2007 number:1 month:09 pages:17-17 https://dx.doi.org/10.2165/00128413-200716060-00061 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1606 2007 1 09 17-17
spelling	10.2165/00128413-200716060-00061 doi (DE-627)SPR035299207 (SPR)00128413-200716060-00061-e DE-627 ger DE-627 rakwb eng CV disorder risks extend beyond COX-2-selectivity of NSAIDs 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2007 Celecoxib (dpeaa)DE-He213 Naproxen (dpeaa)DE-He213 Rofecoxib (dpeaa)DE-He213 Ketorolac (dpeaa)DE-He213 Meloxicam (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1606(2007), 1 vom: Sept., Seite 17-17 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1606 year:2007 number:1 month:09 pages:17-17 https://dx.doi.org/10.2165/00128413-200716060-00061 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1606 2007 1 09 17-17
allfields_unstemmed	10.2165/00128413-200716060-00061 doi (DE-627)SPR035299207 (SPR)00128413-200716060-00061-e DE-627 ger DE-627 rakwb eng CV disorder risks extend beyond COX-2-selectivity of NSAIDs 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2007 Celecoxib (dpeaa)DE-He213 Naproxen (dpeaa)DE-He213 Rofecoxib (dpeaa)DE-He213 Ketorolac (dpeaa)DE-He213 Meloxicam (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1606(2007), 1 vom: Sept., Seite 17-17 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1606 year:2007 number:1 month:09 pages:17-17 https://dx.doi.org/10.2165/00128413-200716060-00061 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1606 2007 1 09 17-17
allfieldsGer	10.2165/00128413-200716060-00061 doi (DE-627)SPR035299207 (SPR)00128413-200716060-00061-e DE-627 ger DE-627 rakwb eng CV disorder risks extend beyond COX-2-selectivity of NSAIDs 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2007 Celecoxib (dpeaa)DE-He213 Naproxen (dpeaa)DE-He213 Rofecoxib (dpeaa)DE-He213 Ketorolac (dpeaa)DE-He213 Meloxicam (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1606(2007), 1 vom: Sept., Seite 17-17 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1606 year:2007 number:1 month:09 pages:17-17 https://dx.doi.org/10.2165/00128413-200716060-00061 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1606 2007 1 09 17-17
allfieldsSound	10.2165/00128413-200716060-00061 doi (DE-627)SPR035299207 (SPR)00128413-200716060-00061-e DE-627 ger DE-627 rakwb eng CV disorder risks extend beyond COX-2-selectivity of NSAIDs 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2007 Celecoxib (dpeaa)DE-He213 Naproxen (dpeaa)DE-He213 Rofecoxib (dpeaa)DE-He213 Ketorolac (dpeaa)DE-He213 Meloxicam (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1606(2007), 1 vom: Sept., Seite 17-17 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1606 year:2007 number:1 month:09 pages:17-17 https://dx.doi.org/10.2165/00128413-200716060-00061 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1606 2007 1 09 17-17
language	English
source	Enthalten in Inpharma weekly 1606(2007), 1 vom: Sept., Seite 17-17 volume:1606 year:2007 number:1 month:09 pages:17-17
sourceStr	Enthalten in Inpharma weekly 1606(2007), 1 vom: Sept., Seite 17-17 volume:1606 year:2007 number:1 month:09 pages:17-17
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Celecoxib Naproxen Rofecoxib Ketorolac Meloxicam
isfreeaccess_bool	false
container_title	Inpharma weekly
publishDateDaySort_date	2007-09-01T00:00:00Z
hierarchy_top_id	373977859
id	SPR035299207
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035299207</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519112536.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2007 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200716060-00061</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035299207</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200716060-00061-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CV disorder risks extend beyond COX-2-selectivity of NSAIDs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2007</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Celecoxib</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Naproxen</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rofecoxib</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ketorolac</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Meloxicam</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1606(2007), 1 vom: Sept., Seite 17-17</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1606</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:1</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:17-17</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200716060-00061</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1606</subfield><subfield code="j">2007</subfield><subfield code="e">1</subfield><subfield code="c">09</subfield><subfield code="h">17-17</subfield></datafield></record></collection>
ppnlink_with_tag_str_mv	@@773@@(DE-627)373977859
format	electronic Article
delete_txt_mv	keep
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2230-6056
topic_title	CV disorder risks extend beyond COX-2-selectivity of NSAIDs Celecoxib (dpeaa)DE-He213 Naproxen (dpeaa)DE-He213 Rofecoxib (dpeaa)DE-He213 Ketorolac (dpeaa)DE-He213 Meloxicam (dpeaa)DE-He213
topic	misc Celecoxib misc Naproxen misc Rofecoxib misc Ketorolac misc Meloxicam
spellingShingle	misc Celecoxib misc Naproxen misc Rofecoxib misc Ketorolac misc Meloxicam CV disorder risks extend beyond COX-2-selectivity of NSAIDs
topic_unstemmed	misc Celecoxib misc Naproxen misc Rofecoxib misc Ketorolac misc Meloxicam
topic_browse	misc Celecoxib misc Naproxen misc Rofecoxib misc Ketorolac misc Meloxicam
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Inpharma weekly
hierarchy_parent_id	373977859
hierarchy_top_title	Inpharma weekly
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)373977859 (DE-600)2127607-9
title	CV disorder risks extend beyond COX-2-selectivity of NSAIDs
ctrlnum	(DE-627)SPR035299207 (SPR)00128413-200716060-00061-e
title_full	CV disorder risks extend beyond COX-2-selectivity of NSAIDs
journal	Inpharma weekly
journalStr	Inpharma weekly
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2007
contenttype_str_mv	txt
container_start_page	17
container_volume	1606
format_se	Elektronische Aufsätze
doi_str_mv	10.2165/00128413-200716060-00061
title_sort	cv disorder risks extend beyond cox-2-selectivity of nsaids
title_auth	CV disorder risks extend beyond COX-2-selectivity of NSAIDs
abstract	© Adis International Ltd 2007
abstractGer	© Adis International Ltd 2007
abstract_unstemmed	© Adis International Ltd 2007
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305
container_issue	1
title_short	CV disorder risks extend beyond COX-2-selectivity of NSAIDs
url	https://dx.doi.org/10.2165/00128413-200716060-00061
remote_bool	true
ppnlink	373977859
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00128413-200716060-00061
up_date	2024-07-03T14:05:19.730Z
_version_	1803566993622695936
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035299207</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519112536.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2007 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200716060-00061</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035299207</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200716060-00061-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CV disorder risks extend beyond COX-2-selectivity of NSAIDs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2007</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Celecoxib</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Naproxen</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rofecoxib</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ketorolac</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Meloxicam</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1606(2007), 1 vom: Sept., Seite 17-17</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1606</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:1</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:17-17</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200716060-00061</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1606</subfield><subfield code="j">2007</subfield><subfield code="e">1</subfield><subfield code="c">09</subfield><subfield code="h">17-17</subfield></datafield></record></collection>
score	7.400546

Nicht das Richtige dabei?

Schreiben Sie uns!

CV disorder risks extend beyond COX-2-selectivity of NSAIDs

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?